<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800991</url>
  </required_header>
  <id_info>
    <org_study_id>HDT-202_F01</org_study_id>
    <nct_id>NCT04800991</nct_id>
  </id_info>
  <brief_title>NuGa (Nutrition for Gastric Cancer Patients)</brief_title>
  <official_title>A Pilot Study to Evaluate the Feasibility and Efficacy of Digital Health Technology for Postoperative Care With Gastrectomy-Treated Patients in Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pilot study is to evaluate the feasibility and efficacy of Rhexium Onco&#xD;
      Nutrition, HDT-202 for post-operative care in patients who have undergone gastrectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. A total of 4 visits will be performed.&#xD;
&#xD;
        2. At the screening visit,subject's written informed consent, assessing the&#xD;
           inclusion/exclusion criteria and assigning enrollment numbers to eligible subjects,&#xD;
           demographic information taking, medical history/medication history taking, vital signs&#xD;
           measuring, physical examination, height and body weight measuring, instructing how to&#xD;
           install/use the investigational device, and administering quality of life&#xD;
           questionnaires.&#xD;
&#xD;
        3. During the treatment period, a total of 3 visits will be performed. To evaluate&#xD;
           feasibility and efficacy, the following procedures will be carried out: vital signs&#xD;
           measuring, physical examination, nutrition assessment/consultation, evaluation of&#xD;
           feasibility for 'subjects', evaluation of feasibility for 'investigators', and adverse&#xD;
           events (AEs)/concomitant medications checking and collecting.&#xD;
&#xD;
        4. During the treatment period, telephone monitoring is conducted depending on the&#xD;
           compliance of subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Actual">October 8, 2021</completion_date>
  <primary_completion_date type="Actual">October 8, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>HDT-202(application)</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score of each domain of the 'feasibility assessment of the investigational device (application)' questionnaire for subjects</measure>
    <time_frame>Week 2 (Visit 2)</time_frame>
    <description>higher scores mean a better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score of each domain of the 'feasibility assessment of the investigational device (application)' questionnaire for subjects</measure>
    <time_frame>Week 6 (Visit 3),</time_frame>
    <description>higher scores mean a better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score of each domain of the 'feasibility assessment of the investigational device (application)' questionnaire for subjects</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>higher scores mean a better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score of each domain of the 'feasibility assessment of the investigational device (website)' questionnaire for investigators</measure>
    <time_frame>Week 6 (Visit 3)</time_frame>
    <description>higher scores mean a better outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (Visit 1) in 'EORTC QLQ-C30' score</measure>
    <time_frame>baseline (Visit 1), Week 10 (Visit 4)</time_frame>
    <description>Refer to Title</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (Visit 1) in 'EORTC QLQ-STO22' score</measure>
    <time_frame>baseline (Visit 1), Week 10 (Visit 4)</time_frame>
    <description>Refer to Title</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (Visit 1) in 'KOQUSS Index' score</measure>
    <time_frame>baseline (Visit 1), Week 10 (Visit 4)</time_frame>
    <description>Refer to Title</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between change from Day 1 in body weight at Week 10 (Visit 4) and calory goal achievement rate</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>Refer to Title</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between change from Day 1 in body weight at Week 10 (Visit 4) and protein intake goal achievement rate</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>Refer to Title</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of each symptom between visits after using the investigational device (application)</measure>
    <time_frame>Week 2 (Visit 2), Week 6 (Visit 3), Week 10 (Visit 4)</time_frame>
    <description>Refer to Title</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigational device(application) usage compliance by age</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>compliance(%) will be measured to day of usage/total period*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigational device(application) usage compliance by gender</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>compliance(%) will be measured to day of usage/total period*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigational device(application) usage compliance by surgery</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>compliance(%) will be measured to day of usage/total period*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigational device(application) usage compliance by stage of disease</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>compliance(%) will be measured to day of usage/total period*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigational device(application) usage compliance by body mass index [BMI] before discharge from hospital</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2, compliance(%) will be measured to day of usage/total period*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigational device(application) usage compliance by status of postoperative anticancer therapy</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>compliance(%) will be measured to day of usage/total period*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigational device(application) usage compliance by underlying disease</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>compliance(%) will be measured to day of usage/total period*100</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of each symptom by baseline characteristics (age, gender, surgery, stage of disease, BMI before discharge from hospital, status of postoperative anticancer therapy, underlying disease)</measure>
    <time_frame>Week 10 (Visit 4)</time_frame>
    <description>Refer to Title</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>Week 2 (Visit 2), Week 6 (Visit 3), Week 10 (Visit 4)</time_frame>
    <description>Incident rate of Adverse Events will be reported</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Rhexium Onco Nutrition(HDT-202)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;subject mobile application&quot; and &quot;Investigator web portal&quot; with no invasive action on the human body</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rhexium Onco Nutrition</intervention_name>
    <description>The research devices in this study are classified into &quot;subject mobile application&quot; and &quot;investigator web portal&quot; with no invasive action on the human body</description>
    <arm_group_label>Rhexium Onco Nutrition(HDT-202)</arm_group_label>
    <other_name>HDT-202</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient who voluntarily signs the informed consent form for this study&#xD;
&#xD;
          2. Age of â‰¥19 years old&#xD;
&#xD;
          3. Patient who has undergone therapeutic gastrectomy after a diagnosis of gastric cancer&#xD;
&#xD;
          4. Able to eat food orally after gastrectomy&#xD;
&#xD;
          5. Patient who possesses an Android OS based mobile device and is capable of using the&#xD;
             investigational device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other cancer or metastasis documented within 5 years prior to screening&#xD;
&#xD;
          2. Ongoing or planned enteral tube feeding or total parenteral nutrition&#xD;
&#xD;
          3. Other clinically significant medical or psychiatric findings based on which the&#xD;
             individual is considered by the investigator to be ineligible&#xD;
&#xD;
          4. Individual who possesses a mobile device on which the application is unable to be&#xD;
             installed and/or run normally for technical reasons&#xD;
&#xD;
          5. Individual who, in the opinion of the investigator, has difficulty understanding how&#xD;
             to use the investigational device or is unlikely to comply with other study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han-Kwang Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgery, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Han-Kwang Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastrectomy</keyword>
  <keyword>postoperative care</keyword>
  <keyword>nutrition</keyword>
  <keyword>Digital health technology</keyword>
  <keyword>Application</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

